Correction to: Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy (Journal of Medicinal Chemistry (2014) 57 (7016-7030) DOI: 10.1021/jm500694p);Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy

Journal of Medicinal Chemistry

Volumn 57, Issue 16, 2014, Pages 7016-7030

  Lee, Kin Sing Stephen ^a   Liu, Jun Yan ^a   Wagner, Karen M ^a   Pakhomova, Svetlana ^d   Dong, Hua ^a   Morisseau, Christophe ^a   Fu, Samuel H ^a   Yang, Jun ^a   Wang, Peng ^a,c   Ulu, Arzu ^a   Mate, Christina A ^a   Nguyen, Long V ^a   Hwang, Sung Hee ^a   Edin, Matthew L ^e   Mara, Alexandria A ^e   Wulff, Heike ^b   Newcomer, Marcia E ^d   Zeldin, Darryl C ^e   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHINA AGRICULTURAL UNIVERSITY   (China)

^d LOUISIANA STATE UNIVERSITY   (United States)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ENZYME; EPOXIDE HYDROLASE INHIBITOR; GABAPENTIN; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID; AMINE; ANALGESIC AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; ENZYME INHIBITOR; EPOXIDE HYDROLASE;

ARTICLE; DIABETIC NEUROPATHY; DRUG POTENCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEUROPATHIC PAIN; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CHEMISTRY; COMPLICATION; DIABETIC NEUROPATHIES; DRUG DESIGN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; NEURALGIA; ORAL DRUG ADMINISTRATION; SOLUBILITY; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TIME FACTOR; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, ORAL; AMINES; ANALGESICS; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY TECHNIQUES, SYNTHETIC; CRYSTALLOGRAPHY, X-RAY; CYCLOHEXANECARBOXYLIC ACIDS; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; DRUG DESIGN; ENZYME INHIBITORS; EPOXIDE HYDROLASES; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MICE; MOLECULAR TARGETED THERAPY; NEURALGIA; RATS, SPRAGUE-DAWLEY; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 84906862150     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.8b00582     Document Type: Erratum

References (64)

1. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States; U.S. Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA, 2011.
2. Calcutt, N. A. Tolerating diabetes: an alternative therapeutic approach for diabetic neuropathy ASN Neuro 2010, 2, 216-217
3. Said, G. Diabetic neuropathy-a review Nature Clin. Pract. Neurol. 2007, 3, 331-340
4. Veves, A.; Backonja, M.; Malik, R. A. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options Pain Med. 2008, 9, 660-674
5. Wong, M.-c.; Chung, J. W. Y.; Wong, T. K. S. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review BMJ n(Br. Med. J.) 2007, 335, 87
6. Spector, A. A. Arachidonic acid cytochrome P450 epoxygenase pathway J. Lipid Res. 2009, 50, S52-S56
7. Morisseau, C.; Inceoglu, B.; Schmelzer, K.; Tsai, H.-J.; Jinks, S. L.; Hegedus, C. M.; Hammock, B. D. Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids J. Lipid Res. 2010, 51, 3481-3490
8. Wagner, K.; Inceoglu, B.; Gill, S. S.; Hammock, B. D. Epoxygenated Fatty Acids and Soluble Epoxide Hydrolase Inhibition: Novel Mediators of Pain Reduction J. Agric. Food Chem. 2011, 59, 2816-2824
9. Morisseau, C.; Hammock, B. D. Impact of Soluble Epoxide Hydrolase and Epoxyeicosanoids on Human Health Annu. Rev. Pharmacol. Toxicol. 2013, 53, 37-58
10. Wagner, K.; Inceoglu, B.; Dong, H.; Yang, J.; Hwang, S. H.; Jones, P.; Morisseau, C.; Hammock, B. D. Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models Eur. J. Pharmacol. 2013, 700, 93-101
11. Inceoglu, B.; Wagner, K. M.; Yang, J.; Bettaieb, A.; Schebb, N. H.; Hwang, S. H.; Morisseau, C.; Haj, F. G.; Hammock, B. D. Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 11390-11395
12. Guedes, A. G. P.; Morisseau, C.; Sole, A.; Soares, J. H. N.; Ulu, A.; Dong, H.; Hammock, B. D. Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis Vet. Anaesth. Analg. 2013, 40, 440-448
13. Tran, L.; Kompa, A. R.; Wang, B. H.; Krum, H. Evaluation of the Effects of Urotensin II and Soluble Epoxide Hydrolase Inhibitor on Skin Microvessel Tone in Healthy Controls and Heart Failure Patients Cardiovasc. Ther. 2012, 30, 295-300
14. Ai, D.; Pang, W.; Li, N.; Xu, M.; Jones, P. D.; Yang, J.; Zhang, Y.; Chiamvimonvat, N.; Shyy, J. Y. J.; Hammock, B. D.; Zhu, Y. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 564-569
15. Brenneis, C.; Sisignano, M.; Coste, O.; Altenrath, K.; Fischer, M. J.; Angioni, C.; Fleming, I.; Brandes, R. P.; Reeh, P. W.; Woolf, C. J.; Geisslinger, G.; Scholich, K. Soluble epoxide hydrolase limits mechanical hyperalgesia during inflammation Mol. Pain 2011, 7, 78
16. Imig, J. D.; Hammock, B. D. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases Nature Rev. Drug Discovery 2009, 8, 794-805
17. Inceoglu, B.; Jinks, S. L.; Schmelzer, K. R.; Waite, T.; Kim, I. H.; Hammock, B. D. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain Life Sci. 2006, 79, 2311-2319
18. Liu, J.-Y.; Lin, Y.-P.; Qiu, H.; Morisseau, C.; Rose, T. E.; Hwang, S. H.; Chiamvimonvat, N.; Hammock, B. D. Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models Eur. J. Pharm. Sci. 2013, 48, 619-627
19. Schmelzer, K. R.; Kubala, L.; Newman, J. W.; Kim, I. H.; Eiserich, J. P.; Hammock, B. D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 9772-9777
20. Ulu, A.; Harris, T. R.; Morisseau, C.; Miyabe, C.; Inoue, H.; Schuster, G.; Dong, H.; Iosif, A.-M.; Liu, J.-Y.; Weiss, R. H.; Chiamvimonvat, N.; Imig, J. D.; Hammock, B. D. Anti-inflammatory Effects of omega-3 Polyunsaturated Fatty Acids and Soluble Epoxide Hydrolase Inhibitors in Angiotensin-II-Dependent Hypertension J. Cardiovasc. Pharmacol. 2013, 62, 285-297
21. Shen, H. C.; Hammock, B. D. Discovery of Inhibitors of Soluble Epoxide Hydrolase: A Target with Multiple Potential Therapeutic Indications J. Med. Chem. 2012, 55, 1789-1808
22. Shen, H. C.; Ding, F.-X.; Wang, S.; Deng, Q.; Zhang, X.; Chen, Y.; Zhou, G.; Xu, S.; Chen, H.-S.; Tong, X.; Tong, V.; Mitra, K.; Kumar, S.; Tsai, C.; Stevenson, A. S.; Pai, L.-Y.; Alonso-Galicia, M.; Chen, X.; Soisson, S. M.; Roy, S.; Zhang, B.; Tata, J. R.; Berger, J. P.; Colletti, S. L. Discovery of a Highly Potent, Selective, and Bioavailable Soluble Epoxide Hydrolase Inhibitor with Excellent ex Vivo Target Engagement J. Med. Chem. 2009, 52, 5009-5012
23. Rose, T. E.; Morisseau, C.; Liu, J.-Y.; Inceoglu, B.; Jones, P. D.; Sanborn, J. R.; Hammock, B. D. 1-Aryl-3-(1-acylpiperidin-4-yl)urea Inhibitors of Human and Murine Soluble Epoxide Hydrolase: Structure-Activity Relationships, Pharmacokinetics, and Reduction of Inflammatory Pain J. Med. Chem. 2010, 53, 7067-7075
24. Reema, K. T.; McAtee, J. J.; Belyanskaya, S.; Brandt, M.; Brown, G. D.; Costell, M. H.; Ding, Y.; Dodson, J. W.; Eisennagel, S. H.; Fries, R. E.; Gross, J. W.; Harpel, M. R.; Holt, D. A.; Israel, D. I.; Jolivette, L. J.; Krosky, D.; Li, H.; Lu, Q.; Mandichak, T.; Roethke, T.; Schnackenberg, C. G.; Schwartz, B.; Shewchuk, L. M.; Xie, W.; Behm, D. J.; Douglas, S. A.; Shaw, A. L.; Marino, J. P., Jr. Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase Bioorg. Med. Chem. Lett. 2013, 23, 3584-3588
25. Podolin, P. L.; Bolognese, B. J.; Foley, J. F.; Long, E., III; Peck, B.; Umbrecht, S.; Zhang, X.; Zhu, P.; Schwartz, B.; Xie, W.; Quinn, C.; Qi, H.; Sweitzer, S.; Chen, S.; Galop, M.; Ding, Y.; Belyanskaya, S. L.; Israel, D. I.; Morgan, B. A.; Behm, D. J.; Marino, J. P., Jr.; Kurali, E.; Barnette, M. S.; Mayer, R. J.; Booth-Genthe, C. L.; Callahan, J. F. In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor Prostaglandins Other Lipid Mediators 2013, 104, 25-31
26. Kim, I.-H.; Nishi, K.; Tsai, H.-J.; Bradford, T.; Koda, Y.; Watanabe, T.; Morisseau, C.; Blanchfield, J.; Toth, I.; Hammock, B. D. Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase Bioorg. Med. Chem. Lett. 2007, 15, 312-323
27. Huang, S.-X.; Cao, B.; Morisseau, C.; Tin, Y.; Hammock, B. D.; Long, Y.-Q. Structure-based optimization of the piperazino-containing 1,3-disubstituted ureas affording sub-nanomolar inhibitors of soluble epoxide hydrolase MedChemComm 2012, 3, 379-384
28. Morisseau, C.; Goodrow, M. H.; Dowdy, D.; Zheng, J.; Greene, J. F.; Sanborn, J. R.; Hammock, B. D. Potent urea and carbamate inhibitors of soluble epoxide hydrolases Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 8849-8854
29. Kim, I.-H.; Tsai, H.-J.; Nishi, K.; Kasagami, T.; Morisseau, C.; Hammock, B. D. 1,3-Disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties J. Med. Chem. 2007, 50, 5217-5226
30. Hwang, S. H.; Tsai, H.-J.; Liu, J.-Y.; Morisseau, C.; Hammock, B. D. Orally bioavailable potent soluble epoxide hydrolase inhibitors J. Med. Chem. 2007, 50, 3825-3840
31. Liu, J. Y.; Tsai, H. J.; Hwang, S. H.; Jones, P. D.; Morisseau, C.; Hammock, B. D. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation Br. J. Pharmacol. 2009, 156, 284-296
32. Jones, P. D.; Tsai, H. J.; Do, Z. N.; Morisseau, C.; Hammock, B. D. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase Bioorg. Med. Chem. Lett. 2006, 16, 5212-5216
33. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Opinion-Drug-target residence time and its implications for lead optimization Nature Rev. Drug Discovery 2006, 5, 730-739
34. Tsai, H.-J.; Hwang, S. H.; Morisseau, C.; Yang, J.; Jones, P. D.; Kasagami, T.; Kim, I.-H.; Hammock, B. D. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs Eur. J. Pharm. Sci. 2010, 40, 222-238
35. Lewis, D. F. V.; Jacobs, M. N.; Dickins, M. Compound lipophilicity for substrate binding to human P450s in drug metabolism Drug Discovery Today 2004, 9, 530-537
36. Hagmann, W. K. The many roles for fluorine in medicinal chemistry J. Med. Chem. 2008, 51, 4359-4369
37. Jeschke, P. The Unique Role of Halogen Substituents in the Design of Modern Crop Protection Compounds; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2012.
38. Lee, K. S. S.; Morisseau, C.; Yang, J.; Wang, P.; Hwang, S. H.; Hammock, B. D. Forster resonance energy transfer competitive displacement assay for human soluble epoxide hydrolase Anal. Biochem. 2013, 434, 259-268
39. Gomez, G. A.; Morisseau, C.; Hammock, B. D.; Christianson, D. W. Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids Protein Sci. 2006, 15, 58-64
40. Allen, F. H.; Kennard, O.; Watson, D. G.; Brammer, L.; Orpen, A. G.; Taylor, R. Tables of bond lengths determined by x-ray and neutron diffraction. Part 1. Bond lengths in organic compounds J. Chem. Soc., Perkin Trans. 1987, 2, S1-S19
41. Ulu, A.; Appt, S. E.; Morisseau, C.; Hwang, S. H.; Jones, P. D.; Rose, T. E.; Dong, H.; Lango, J.; Yang, J.; Tsai, H. J.; Miyabe, C.; Fortenbach, C.; Adams, M. R.; Hammock, B. D. Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys Br. J. Pharmacol. 2012, 165, 1401-1412
42. Vickers, A. E. M.; Sinclair, J. R.; Zollinger, M.; Heitz, F.; Glanzel, U.; Johanson, L.; Fischer, V. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions Drug Metab. Dispos. 1999, 27, 1029-1038
43. Austin, R. P.; Barton, P.; Cockroft, S. L.; Wenlock, M. C.; Riley, R. J. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties Drug Metab. Dispos. 2002, 30, 1497-1503
44. O'Brien, A. J.; Fullerton, J. N.; Massey, K. A.; Auld, G.; Sewell, G.; James, S.; Newson, J.; Karra, E.; Winstanley, A.; Alazawi, W.; Garcia-Martinez, R.; Cordoba, J.; Nicolaou, A.; Gilroy, D. W. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E-2 Nature Med. 2014, 20, 522-527
45. Wu, J.; LoRusso, P. M.; Matherly, L. H.; Li, J. Implications of Plasma Protein Binding for Pharmacokinetics and Pharmacodynamics of the gamma-Secretase Inhibitor RO4929097 Clin. Cancer. Res. 2012, 18, 2066-2079
46. Smith, D. A.; Di, L.; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery Nature Rev. Drug Discovery 2010, 9, 929-939
47. Morisseau, C.; Merzlikin, O.; Lin, A.; He, G.; Feng, W.; Padilla, I.; Denison, M. S.; Pessah, I. N.; Hammock, B. D. Toxicology in the fast lane: application of high-throughput bioassays to detect modulation of key enzymes and receptors Environ. Health Perspect. 2009, 117, 1867-1872
48. Zeldin, D. C.; Moomaw, C. R.; Jesse, N.; Tomer, K. B.; Beetham, J.; Hammock, B. D.; Wu, S. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway Arch. Biochem. Biophys. 1996, 330, 87-96
49. Wu, S.; Moomaw, C. R.; Tomer, K. B.; Falck, J. R.; Zeldin, D. C. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart J. Biol. Chem. 1996, 271, 3460-3468
50. Graves, J. P.; Edin, M. L.; Bradbury, J. A.; Gruzdev, A.; Cheng, J.; Lih, F. B.; Masinde, T. A.; Qu, W.; Clayton, N. P.; Morrison, J. P.; Tomer, K. B.; Zeldin, D. C. Characterization of four new mouse cytochrome P450 enzymes of the CYP2J subfamily Drug Metab. Dispos. 2013, 41, 763-773
51. Chiang, P.-C.; Ran, Y.; Chou, K.-J.; Cui, Y.; Wong, H. Investigation of utilization of nanosuspension formulation to enhance exposure of 1,3-dicyclohexylurea in rats: preparation for PK/PD study via subcutaneous route of nanosuspension drug delivery Nanoscale Res. Lett. 2011, 6, 413
52. Chiang, P.-C.; La, H.; Zhang, H.; Wong, H. Systemic Concentrations Can Limit the Oral Absorption of Poorly Soluble Drugs: An Investigation of Non-Sink Permeation Using Physiologically Based Pharmacokinetic Modeling Mol. Pharmacol. 2013, 10, 3980-3988
53. Jones, P. D.; Tsai, H.-J.; Do, Z. N.; Morisseau, C.; Hammock, B. D. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase Bioorg. Med. Chem. Lett. 2006, 16, 5212-5216
54. Borhan, B.; Mebrahtu, T.; Nazarian, S.; Kurth, M. J.; Hammock, B. D. Improved radiolabeled substrates for soluble epoxide hydrolase Anal. Biochem. 1995, 231, 188-200
55. Jones, P. D.; Wolf, N. M.; Morisseau, C.; Whetstone, P.; Hock, B.; Hammock, B. D. Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies Anal. Biochem. 2005, 343, 66-75
56. Matveeva, E. G.; Morisseau, C.; Goodrow, M. H.; Mullin, C.; Hammock, B. D. Tryptophan Fluorescence Quenching by Enzyme Inhibitors As a Tool for Enzyme Active Site Structure Investigation: Epoxide Hydrolase Curr. Pharm. Biotechnol. 2009, 10, 589-599
57. Schebb, N. H.; Huby, M.; Morisseau, C.; Hwang, S. H.; Hammock, B. D. Development of an online SPE-LC-MS-based assay using endogenous substrate for investigation of soluble epoxide hydrolase (sEH) inhibitors Anal. Bioanal. Chem. 2011, 400, 1359-1366
58. Wolf, N. M.; Morisseau, C.; Jones, P. D.; Hock, B.; Hammock, B. D. Development of a high-throughput screen for soluble epoxide hydrolase inhibition Anal. Biochem. 2006, 355, 71-80
59. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode Macromol. Crystallogr., Part A 1997, 276, 307-326
60. Winter, G. xia2: an expert system for macromolecular crystallography data reduction J. Appl. Crystallogr. 2010, 43, 186-190
61. Bailey, S. The CCP4 Suite-programs for Protein Crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763
62. Painter, J.; Merritt, E. A. TLSMD web server for the generation of multi-group TLS models J. Appl. Crystallogr. 2006, 39, 109-111
63. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 486-501
64. Aley, K. O.; Levine, J. D. Rapid onset pain induced by intravenous streptozotocin in the rat J. Pain 2001, 2, 146-150